Cargando…

Treatment of anastomotic leak after oesophagectomy for oesophageal cancer: large, collaborative, observational TENTACLE cohort study

BACKGROUND: Anastomotic leak is a severe complication after oesophagectomy. Anastomotic leak has diverse clinical manifestations and the optimal treatment strategy is unknown. The aim of this study was to assess the efficacy of treatment strategies for different manifestations of anastomotic leak af...

Descripción completa

Detalles Bibliográficos
Autores principales: Ubels, Sander, Verstegen, Moniek H P, Klarenbeek, Bastiaan R, Bouwense, Stefan, van Berge Henegouwen, Mark I, Daams, Freek, van Det, Marc J, Griffiths, Ewen A, Haveman, Jan Willem, Heisterkamp, Joos, Nieuwenhuijzen, Grard, Polat, Fatih, Schouten, Jeroen, Siersema, Peter D, Singh, Pritam, Wijnhoven, Bas, Hannink, Gerjon, van Workum, Frans, Rosman, Camiel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364505/
https://www.ncbi.nlm.nih.gov/pubmed/37196149
http://dx.doi.org/10.1093/bjs/znad123
_version_ 1785076857785286656
author Ubels, Sander
Verstegen, Moniek H P
Klarenbeek, Bastiaan R
Bouwense, Stefan
van Berge Henegouwen, Mark I
Daams, Freek
van Det, Marc J
Griffiths, Ewen A
Haveman, Jan Willem
Heisterkamp, Joos
Nieuwenhuijzen, Grard
Polat, Fatih
Schouten, Jeroen
Siersema, Peter D
Singh, Pritam
Wijnhoven, Bas
Hannink, Gerjon
van Workum, Frans
Rosman, Camiel
author_facet Ubels, Sander
Verstegen, Moniek H P
Klarenbeek, Bastiaan R
Bouwense, Stefan
van Berge Henegouwen, Mark I
Daams, Freek
van Det, Marc J
Griffiths, Ewen A
Haveman, Jan Willem
Heisterkamp, Joos
Nieuwenhuijzen, Grard
Polat, Fatih
Schouten, Jeroen
Siersema, Peter D
Singh, Pritam
Wijnhoven, Bas
Hannink, Gerjon
van Workum, Frans
Rosman, Camiel
author_sort Ubels, Sander
collection PubMed
description BACKGROUND: Anastomotic leak is a severe complication after oesophagectomy. Anastomotic leak has diverse clinical manifestations and the optimal treatment strategy is unknown. The aim of this study was to assess the efficacy of treatment strategies for different manifestations of anastomotic leak after oesophagectomy. METHODS: A retrospective cohort study was performed in 71 centres worldwide and included patients with anastomotic leak after oesophagectomy (2011–2019). Different primary treatment strategies were compared for three different anastomotic leak manifestations: interventional versus supportive-only treatment for local manifestations (that is no intrathoracic collections; well perfused conduit); drainage and defect closure versus drainage only for intrathoracic manifestations; and oesophageal diversion versus continuity-preserving treatment for conduit ischaemia/necrosis. The primary outcome was 90-day mortality. Propensity score matching was performed to adjust for confounders. RESULTS: Of 1508 patients with anastomotic leak, 28.2 per cent (425 patients) had local manifestations, 36.3 per cent (548 patients) had intrathoracic manifestations, 9.6 per cent (145 patients) had conduit ischaemia/necrosis, 17.5 per cent (264 patients) were allocated after multiple imputation, and 8.4 per cent (126 patients) were excluded. After propensity score matching, no statistically significant differences in 90-day mortality were found regarding interventional versus supportive-only treatment for local manifestations (risk difference 3.2 per cent, 95 per cent c.i. −1.8 to 8.2 per cent), drainage and defect closure versus drainage only for intrathoracic manifestations (risk difference 5.8 per cent, 95 per cent c.i. −1.2 to 12.8 per cent), and oesophageal diversion versus continuity-preserving treatment for conduit ischaemia/necrosis (risk difference 0.1 per cent, 95 per cent c.i. −21.4 to 1.6 per cent). In general, less morbidity was found after less extensive primary treatment strategies. CONCLUSION: Less extensive primary treatment of anastomotic leak was associated with less morbidity. A less extensive primary treatment approach may potentially be considered for anastomotic leak. Future studies are needed to confirm current findings and guide optimal treatment of anastomotic leak after oesophagectomy.
format Online
Article
Text
id pubmed-10364505
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-103645052023-07-31 Treatment of anastomotic leak after oesophagectomy for oesophageal cancer: large, collaborative, observational TENTACLE cohort study Ubels, Sander Verstegen, Moniek H P Klarenbeek, Bastiaan R Bouwense, Stefan van Berge Henegouwen, Mark I Daams, Freek van Det, Marc J Griffiths, Ewen A Haveman, Jan Willem Heisterkamp, Joos Nieuwenhuijzen, Grard Polat, Fatih Schouten, Jeroen Siersema, Peter D Singh, Pritam Wijnhoven, Bas Hannink, Gerjon van Workum, Frans Rosman, Camiel Br J Surg Original Article BACKGROUND: Anastomotic leak is a severe complication after oesophagectomy. Anastomotic leak has diverse clinical manifestations and the optimal treatment strategy is unknown. The aim of this study was to assess the efficacy of treatment strategies for different manifestations of anastomotic leak after oesophagectomy. METHODS: A retrospective cohort study was performed in 71 centres worldwide and included patients with anastomotic leak after oesophagectomy (2011–2019). Different primary treatment strategies were compared for three different anastomotic leak manifestations: interventional versus supportive-only treatment for local manifestations (that is no intrathoracic collections; well perfused conduit); drainage and defect closure versus drainage only for intrathoracic manifestations; and oesophageal diversion versus continuity-preserving treatment for conduit ischaemia/necrosis. The primary outcome was 90-day mortality. Propensity score matching was performed to adjust for confounders. RESULTS: Of 1508 patients with anastomotic leak, 28.2 per cent (425 patients) had local manifestations, 36.3 per cent (548 patients) had intrathoracic manifestations, 9.6 per cent (145 patients) had conduit ischaemia/necrosis, 17.5 per cent (264 patients) were allocated after multiple imputation, and 8.4 per cent (126 patients) were excluded. After propensity score matching, no statistically significant differences in 90-day mortality were found regarding interventional versus supportive-only treatment for local manifestations (risk difference 3.2 per cent, 95 per cent c.i. −1.8 to 8.2 per cent), drainage and defect closure versus drainage only for intrathoracic manifestations (risk difference 5.8 per cent, 95 per cent c.i. −1.2 to 12.8 per cent), and oesophageal diversion versus continuity-preserving treatment for conduit ischaemia/necrosis (risk difference 0.1 per cent, 95 per cent c.i. −21.4 to 1.6 per cent). In general, less morbidity was found after less extensive primary treatment strategies. CONCLUSION: Less extensive primary treatment of anastomotic leak was associated with less morbidity. A less extensive primary treatment approach may potentially be considered for anastomotic leak. Future studies are needed to confirm current findings and guide optimal treatment of anastomotic leak after oesophagectomy. Oxford University Press 2023-05-17 /pmc/articles/PMC10364505/ /pubmed/37196149 http://dx.doi.org/10.1093/bjs/znad123 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
Ubels, Sander
Verstegen, Moniek H P
Klarenbeek, Bastiaan R
Bouwense, Stefan
van Berge Henegouwen, Mark I
Daams, Freek
van Det, Marc J
Griffiths, Ewen A
Haveman, Jan Willem
Heisterkamp, Joos
Nieuwenhuijzen, Grard
Polat, Fatih
Schouten, Jeroen
Siersema, Peter D
Singh, Pritam
Wijnhoven, Bas
Hannink, Gerjon
van Workum, Frans
Rosman, Camiel
Treatment of anastomotic leak after oesophagectomy for oesophageal cancer: large, collaborative, observational TENTACLE cohort study
title Treatment of anastomotic leak after oesophagectomy for oesophageal cancer: large, collaborative, observational TENTACLE cohort study
title_full Treatment of anastomotic leak after oesophagectomy for oesophageal cancer: large, collaborative, observational TENTACLE cohort study
title_fullStr Treatment of anastomotic leak after oesophagectomy for oesophageal cancer: large, collaborative, observational TENTACLE cohort study
title_full_unstemmed Treatment of anastomotic leak after oesophagectomy for oesophageal cancer: large, collaborative, observational TENTACLE cohort study
title_short Treatment of anastomotic leak after oesophagectomy for oesophageal cancer: large, collaborative, observational TENTACLE cohort study
title_sort treatment of anastomotic leak after oesophagectomy for oesophageal cancer: large, collaborative, observational tentacle cohort study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364505/
https://www.ncbi.nlm.nih.gov/pubmed/37196149
http://dx.doi.org/10.1093/bjs/znad123
work_keys_str_mv AT ubelssander treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT verstegenmoniekhp treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT klarenbeekbastiaanr treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT bouwensestefan treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT vanbergehenegouwenmarki treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT daamsfreek treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT vandetmarcj treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT griffithsewena treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT havemanjanwillem treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT heisterkampjoos treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT nieuwenhuijzengrard treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT polatfatih treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT schoutenjeroen treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT siersemapeterd treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT singhpritam treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT wijnhovenbas treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT hanninkgerjon treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT vanworkumfrans treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT rosmancamiel treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy
AT treatmentofanastomoticleakafteroesophagectomyforoesophagealcancerlargecollaborativeobservationaltentaclecohortstudy